Accelerate Drug Discovery With AI Solutions

Digital & AI Solutions With the Life Sciences companies of Danaher Visit DHRLS.CO 06 Case Study Eliminating Analytical Data Bottlenecks and Streamlining Drug Discovery 07 Case Study Improving the Efficiency and Quality of Advanced Imaging and Analysis 08 Case Study Collaborative Data management: The Key to Accelerating Drug Development Table of Contents 05 Executive Summary Supporting Drug Pipelines with a comprehensive backbone in silico 3 improve drug candidate success rates by 25% 4 5 Supporting Drug Pipelines with a comprehensive backbone in silico Executive Summary New biologic drugs are quickly becoming the new standard of care for many diseases, including those previously thought to be untreatable. It is imperative to select analytical methods that allow accurate and precise candidate screening for efficacy and safety. Despite their importance, the useful data gathered from these analytical methods alone may not speed up critical timelines. The sheer volumes of analytical data generated during drug discovery and development for these new drugs are challenging to work through. As these processes become faster and more high-throughput, the downstream surge in complex data becomes increasingly challenging to manage, necessitating additional time and expertise from skilled scientists. Combining analytical methods with a comprehensive, AI-powered data backbone is crucial to transforming biopharmaceutical drug discovery and development. Innovative instrumentation can allow more in-depth studies and researchers can look forward to obtaining more complete libraries of information in minimal time. However, scientists also need to act on these volumes of data. By using in silico data analysis and modeling techniques, researchers can find successful candidates faster and shorten the time required to develop lifesaving therapies. Data capture from the instrument and instant integration into a data backbone can make these data accessible to researchers anywhere. By working with leaders in science and technology, researchers can establish a data backbone for analysis and develop predictive methods that model conditions seen in manufacturing and purification before that compound has even been designed. Predictive modeling with AI/ML can be used to not only predict the behavior and interactions of therapeutic candidates, but also the processes and equipment that would be needed to produce them at scale. Unlock the potential of your laboratory by tapping into solutions that consider all facets of complex workflows, encompassing instrumentation, software, and optimized methods. To learn more about these solutions, contact an expert at the Life Sciences companies of Danaher today. ©2025 DH Life Sciences, LLC. All Rights Reserved. For Research Use Only. Not for use in Diagnostic Procedures. Together, we see a way to Improving the efficiency and quality of advanced imaging and analysis Case Study 2 Obtaining high-quality tissue sample images is essential during drug screening and development. For example, high-quality spatial imaging can facilitate cancer research, such as evaluating the tumor microenvironment and analyzing human organoids. However, the difficulty in obtaining clear and representative sample data due to heterogeneity within tissue samples and the need to maintain sample culture and incubation conditions can make tissue imaging complicated. Sample preparation can also be challenging. Many stains can be involved in the process, and antibodies often need to penetrate specific tissues to reach antigens. Complexities associated with tissue imaging do not end there. Capturing images and analyzing them manually is time-consuming, inefficient and subjective. These bottlenecks are exacerbated when using techniques such as confocal microscopy and when using multiple antibody stains and incubations, which require more precise and involved sample preparation. Imaging instruments that automate image capture and high-content image analysis with guided workflows and software for image segmentation and classification, can enable laboratories to go beyond one or two analysis parameters and generate more valuable data from high-content image capture. If a picture is worth one thousand words, multiplexed images may be worth a few publications. Maximizing data yield from samples and ensuring every appropriate insight is being gleaned from tissues can seem like an endless task. Without appropriate technology, it can become extremely difficult to capture all the required data from a single biopsy or tissue sample. Precise, open multiplexing solutions, can help researchers transform tissue research with multiple antibodies, facilitating high-quality automated image capture from multiple conditions in parallel. Automated image processing and feature extraction across acquired images can enable visualization, identification and quantification of biomarkers and other research areas for maximizing insights. Unlocking productivity, removing bottlenecks in workflows and improving quality by reducing subjectivity resulting from human error calls for scalable automation. At the Life Sciences companies of Danaher we help pioneer more effective treatments and develop more efficient workflows. 7 Eliminating Analytical Data Bottlenecks and Streamlining Drug Discovery Case Study 1 Advanced analytical methods have become indispensable in drug development pipelines. Accurate analytical data provides crucial insights for informed decision making, ensuring that the development of life-changing therapies is supported by repeatable data. For example, mass spectrometry (MS) as an analytical method is indispensable in defining critical quality attributes (CQAs) of pharmaceutical products, such as mass, peptide composition, and biological potency. Likewise, flow cytometry is essential for understanding CQAs for validating antigen binding or the correct cellular phenotype. However, as processes such as analytical sample preparation and instrumentation become faster and more high-throughput, the downstream surge in complex data becomes increasingly challenging to manage, necessitating additional time and expertise from skilled scientists. Take for instance, the amount of time and effort required to manually analyze large volumes of complex data obtained from in-depth mass spectrometric studies. Innovative instrumentation can allow more in-depth studies and researchers can look forward to obtaining high volumes of information in minimal time. However, scientists also need to act on these volumes of data – protein ID workflows within SCIEX OS software allow researchers to not only identify the protein groups and precursors swiftly with the aid of in silico libraries, but also accurately quantify protein groups, enhancing productivity, and streamline drug candidate screening. By using an in silico-generated library, SCIEX’s Zeno SWATH DIA method eliminates the need to build spectral libraries from scratch, improving the speed of experimental runs. Data bottlenecks during drug development can significantly diminish the gains accrued from the automation of analytical methods. Unlock the potential of your laboratory by tapping into solutions that consider all facets of complex workflows, encompassing instrumentation, software, and optimized methods. 6 8 9 Collaborative Data Management: The Key to Accelerating Drug Development Case Study 3 AI is enabling organizations to make the most of large datasets by leveraging data in new, strategic ways that were not possible or pragmatic when data analysis is done by hand. For the biopharma industry, data-driven insights can fuel innovation and efficiency in drug discovery and development. Organizations with collaborative, crossfunctional teams working on a single unified goal can capture, manage, and process huge volumes of data. On the other hand, organizations with laboratories and teams working in silos may fail to realize the full potential of comprehensive data management. For example, data pipelines designed without input from scientists and technical SMEs may not sufficiently contextualize data for data scientists, impeding the usability and practicality of this approach. This can lead to inefficiencies in operations and unnecessary delays in project execution. A workaround to this situation is to foster a collaborative environment where different teams come together to achieve digital transformation. With automated, increasingly complex analytical workflows, organizations are facing the challenge of dealing with increasingly vast amounts of data generated by routine procedures. As analytical methods become more complex and high-throughput, researchers need to invest time and expertise to generate insights. To help researchers capitalize on these insights and accelerate drug discovery, organizations must ensure that the data is accessible and capable of delivering automated analytics to add value and empower researchers. A culture that fosters cross-functional collaboration and makes data accessible across entire organizations will see the greatest benefit from AI-driven data management and handling. At the Life Sciences companies of Danaher, we focus on innovative solutions that make leading-edge scientific discovery possible. From enabling initial molecular screens to developing analytical validation for manufacturing, our solutions can streamline your journey of digital transformation, powering a healthier, more sustainable tomorrow. 8 9 Phenomenex We see a way to accelerate progress in the Separation Sciences, advancing the future of analysis and investigation for those on the front line of scientific discovery and development. Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government, and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. Learn more about Phenomenex Abcam We believe the scientific community goes further, faster when we go there together. That’s why we partner with life scientists around the world to create innovative research solutions for cancer, neurological disorders, infectious diseases and more. Learn more about Abcam SCIEX We see a way to use the power of precision to drive scientific breakthroughs, achieve better outcomes and advance human wellness. SCIEX has led the field of mass spectrometry and capillary electrophoresis for over 50 years, pioneering innovative solutions for the precision detection of quantification of molecules. Our products and services have supported thousands of scientists and influenced life-changing research that has positively impacted the lives of people around the world. Learn more about SCIEX 10 11 About our Brands The Life Sciences companies of Danaher Beckman Coulter Life Sciences We see a way to expedite the development of life-saving therapeutics through the use of innovative instruments and reagents. Beckman Coulter Life Sciences is a leading developer of scientific research technologies that primarily serve the academia and pharmaceutical markets. The company also develops and manufacture solutions for clinical research and for applied markets such as agricultural, food and beverage, gas and oil, aerospace, and several others. Learn more about Beckman Coulter Life Sciences IDBS We see a way to harness the power of data to unlock faster and smarter decisions in biopharma research, development, and manufacturing. IDBS provides purpose-built software solutions to address data management challenges prominent across the biopharma lifecycle and supply chain. IDBS’ groundbreaking technologies, including the world’s first BioPharma Lifecycle Management (BPLM) solution, streamline the capture, analysis, reporting and sharing of data to accelerate the next generation of life-changing therapeutics. Learn more about IDBS Leica Microsystems We see a way to transform scientific discovery with a combination of cuttingedge microscopes and ground-breaking digital analysis. Leica Microsystems is one of the market leaders in microscopy and scientific imaging. The company develops highly advanced instruments for the analysis of microstructures and nanostructures – increasingly harnessing the power of machine learning, automation, and data analytics to provide greater insights to scientists than ever before. Learn more about Leica Microsystems Molecular Devices We see a way to enable the life science laboratories of the future, where innovative technologies and novel research converge to advance discovery and drive safer therapeutics for patients. Molecular Devices is one of the leading providers of high-performance bioanalytical measurement solutions for the life science and biopharmaceutical research markets. The company’s integrated hardware and software solutions enable start-to-finish automated workflows for cell line development, 3D biology and drug screening. Learn more about Molecular Devices Genedata Genedata provides enterprise software solutions that digitalize and automate data-rich and complex biopharma R&D processes. Learn more about Genedata For research use only. Not for use in diagnostic procedures. ©2025 DH Life Sciences, LLC, DH Tech. Dev. Pte. Ltd., Genedata AG, Leica Microsystems CMS GmbH, Wetzlar, Germany. Subject to modifications., Molecular Devices, LLC., ID Business Solutions, Ltd. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries. Visit DHRLS.CO Our experts apply Danaher’s life science technologies and proven solutions, working with you to design and implement integrated workflow solutions that can dramatically reduce time & costs of bringing advanced therapies to market.